Thalia Therapeutics

Default features description for sign up page.

Regulatory news

Home

Media

AIM Rule 26

Open Sans

THALIA THERAPEUTICS INVESTOR CENTRE

Drug Discovery Today

Current approaches to treating cancer are falling short and driving the need for new therapeutic strategies that reduce the toxicity associated with chemotherapy and improve the efficacy of immunotherapy.
 
In an article published by Drug Discovery Today, Nigel Theobald, CEO, N4 Pharma and David Templeton, Technical Director, N4 Pharma, explore how the dual delivery of small interfering ribonucleic acid (siRNA) via a suitable delivery system, such as Nuvec®, could herald a new era of treatment efficiency in cancer.

A drug delivery strategy emerges that has the potential to transform cancer therapy